Newsfile Corp
01 Aug 2026, 01:10 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
FDA staff raised concerns regarding the effectiveness data for Capricor Therapeutics' cell therapy (deramiocel) for a heart condition related to Duchenne muscular dystrophy. — FDA efficacy concerns for a primary drug candidate are a critical failure risk that directly threatens the company's core valuation.
-0.90The Rosen Law Firm has launched an investigation into potential securities claims against Capricor Therapeutics for allegedly issuing misleading business information. — Class action lawsuits create additional legal liabilities and overhead, though they typically follow the price drop caused by the underlying negative news.
-0.30Which stocks this story touches
FDA concerns over therapy effectiveness led to a 64% share price plunge and a securities class action investigation.
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is mentioned as being subject to a securities class action investigation.
The company is mentioned in the context of a securities class action lawsuit deadline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
57m ago
